Category: clinical study retractions

Updated: Ohio State revokes PhD of co-author of now-retracted paper on shooter video games

Jodi Whitaker, via University of Arizona

[This post, which at 1200 UTC 8/25/17 originally reported on the then-upcoming vote, has been updated at 1800 UTC 8/25/17 to include the results of the vote.]

A researcher who co-authored a paper about video games that was retracted earlier this year has had her PhD from The Ohio State University revoked.

As WOSU reported this afternoon, the vote today of the university’s Board of Trustees was unanimous. The scheduled vote on whether to revoke Jodi Whitaker’s degree was first reported yesterday by The Columbus Dispatch.

While a graduate student at Ohio State, Whitaker was co-author of a paper that claimed to find that first-person shooter video games improved marksmanship. As we’ve reported, the paper, published online in 2012, was retracted earlier this year, two years after a university committee was alerted to irregularities in the data by two outside researchers.

The controversy over the paper became heated at times. Continue reading Updated: Ohio State revokes PhD of co-author of now-retracted paper on shooter video games

Given “wrong pathology slides,” heart journal retracts paper

A cardiology journal has retracted a paper after the authors were unable to provide correct pathology slides to replace the wrong ones submitted with the original manuscript.

The paper is titled “Aortic Valve Endocarditis and Coronary Angiography With Cerebral Embolic Protection,” published on April 10, 2017 in The Journal of the American College of Cardiology: Cardiovascular Interventions (JACC:CI). It has not yet been cited, according to Clarivate Analytics’ Web of Science.

JACC:CI retracted the paper on Aug. 14, providing this notice: Continue reading Given “wrong pathology slides,” heart journal retracts paper

Hey, that’s my case study: Another retraction after doctors claim rights to case write-up

A group of researchers have retracted their 2016 case report about a rare dermatologic disorder in the wake of disputes about authorship and institutional approval.

The paper describes a young boy with Job’s Syndrome, in which patients experience painful, itchy and frequently disfiguring skin lesions, along with a constellation of other possible symptoms. The condition is extremely rare, occurring in less than one in 1 million births.

This isn’t the first time a journal has retracted a case study after another group of authors claimed ownership of the case. Earlier this year, we covered a retraction from a neuro-ophthalmology journal after the doctors who treated a patient suffering from a gruesome eye trauma took issue with the fact that radiologists had already published their diagnostic images as a case study.

According to the notice for this latest retraction:

Continue reading Hey, that’s my case study: Another retraction after doctors claim rights to case write-up

Released FDA docs reveal details of agency’s (failed) attempt to retract paper

Earlier this year, a raging controversy regarding a new drug spilled into the pages of a leading medical journal: the head of the U.S. Food and Drug Administration and another official publicly called for the retraction or correction of a peer-reviewed article about the drug. They didn’t get their wish. Now, documents released by the FDA via a lawsuit shed light on the attempt — and show how tricky it can be to correct the official record.

The controversy surrounds the approval of eteplirsen, a drug approved last September to treat Duchenne Muscular Dystrophy, a rare but invariably fatal disease that strikes (mostly) young boys. Eteplirsen was approved over the objections of the FDA team that reviewed the drug, which determined that there was insufficient evidence to approve the drug.

But the controversy didn’t end within the walls of the FDA complex. Ellis Unger, who led the review team, believed that one of the principal studies of the drug, published in the Annals of Neurology, was “misleading” because it was based on “unreliable data.” So in early November, Unger, joined by the then-head of the FDA, Robert Califf, took the extremely rare move of writing to the editor of the journal to “urge that the paper be corrected or retracted….”

According to the documents, the authors of the Annals article did, in fact, agree to correct the article.

On November 9, 2016, Clifford Saper, Annals‘ editor in chief, wrote to Califf and Unger:

Continue reading Released FDA docs reveal details of agency’s (failed) attempt to retract paper

Journal knew about problems in a high-profile study before it came out — and did nothing for over a month

In June, Gene Emery, a journalist for Reuters Health, was assigned to write a story about an upcoming paper in the Journal of the American College of Cardiology, set to come off embargo and be released to the public in a few days. Pretty quickly, he noticed something seemed off.

Emery saw that the data presented in the tables of the paper — about awareness of the problem of heart disease among women and their doctors — didn’t seem to match the authors’ conclusions. For instance, on a scale of 1 to 5 rating preparedness to assess female patients’ risk (with 5 being the most prepared), 64% of doctors answered 4 or 5; but the paper said “only a minority” of doctors felt well-prepared (findings echoed in an accompanying press release). On Monday June 19, four days before the paper was set to publish, Emery told the corresponding author — C. Noel Bairey Merz, Medical Director of the Women’s Heart Center at Cedars-Sinai in Los Angeles — about the discrepancy; she told him to rely on the data in the table.

But the more Emery and his editors looked, the more problems they found with the paper. They alerted the journal hours before it was set to publish, hoping that was enough to halt the process. It wasn’t.

Continue reading Journal knew about problems in a high-profile study before it came out — and did nothing for over a month

What should journals do when peer reviewers do not disclose potential conflicts?

Peer reviewers, like authors, are supposed to declare any potential conflicts of interest. But what happens when they don’t?

Take this case: In a court transcript from Feb. 23, 2017, Bryan Hardin testified that he was a peer reviewer on a 2016 paper in Critical Reviews in Toxicology, which found that asbestos does not increase the risk of cancer. In the deposition, Hardin—who works at the consulting firm Veritox—also said that he has testified in asbestos litigation on behalf of automakers, such as Ford, General Motors, and Chrysler, but said he had not disclosed these relationships to the journal.

Last year, the first author of the 2016 review withdrew a paper from another journal (by the same publisher) which concluded asbestos roofing products are safe, following several criticisms — including not disclosing the approving editor’s ties to the asbestos industry. In this latest case, the journal told us it believes the review process for the paper was up to snuff, but two outside experts we consulted said they believed Hardin’s relationships — and failure to disclose them — should give the journal pause.

We obtained a copy of the transcript from Christian Hartley, who was representing a man suing a mining company because the man developed cancer after being exposed to asbestos at work. When Hartley asked Hardin whether he had told the journal about testifying for companies involved in asbestos litigation, Hardin responded:

Continue reading What should journals do when peer reviewers do not disclose potential conflicts?

JAMA tells readers: “Caution advised.” Here’s why.

Last week, JAMA issued some unusual notices, letting readers know they should use caution when reading an editorial and letters associated with now-retracted articles by a bone researcher in Japan.

The notices — for papers by Yoshihiro Sato, now up to 14 retractions — remind readers not to heed the results of the now-retracted papers, and alert them to read any associated materials (specifically, an editorial in JAMA and letters in JAMA Internal Medicine) with caution.

The text of the notices describes them as “formal correction notices;” we asked Annette Flanagin, executive managing editor at The JAMA Network, why they chose that approach, instead of an expression of concern or retraction:

Continue reading JAMA tells readers: “Caution advised.” Here’s why.

Third retraction for former rising star found guilty of misconduct

A once-prominent researcher in the field of infectious disease — who was found guilty of misconduct last year— has had a third paper retracted, a 2006 article in PNAS.

Last year, the University of Dundee in Scotland found that Robert Ryan had committed research misconduct, which included misrepresenting clinical data and duplicating images in a dozen different publications. After a failed attempt to appeal the decision, Ryan resigned.

In April, we covered Ryan’s first two retractions – a 2012 paper in Molecular Microbiology, which cited image errors, and a 2011 paper in Journal of Bacteriology, which cited image duplication.

Now, PNAS has retracted a 2006 paper, which cites potential image duplication as well as “irregularities” in the data.

Here’s the retraction notice for “Cell–cell signaling in Xanthomonas campestris involves an HD-GYP domain protein that functions in cyclic di-GMP turnover:”

Continue reading Third retraction for former rising star found guilty of misconduct

Researchers retract a paper when they realize they had sequenced the wrong snail’s genome

Researchers in China thought they had sequenced the genomes of two snails that help transmit diseases to other species — an important first step to stopping the spread. But their hopes were soon dashed after they realized they had misidentified one of the snails.

The researchers published their findings earlier this year in the journal Parasites & Vectors. In the paper, the authors stressed that understanding the genetic makeup of these molluscs is important because many “freshwater snails are intermediate hosts for flatworm parasites and transmit infectious diseases” to humans and other animals. They also acknowledged that identifying snail species from their appearance alone can be tricky. Continue reading Researchers retract a paper when they realize they had sequenced the wrong snail’s genome

Publisher won’t retract two papers, despite university’s request

Jens Förster

Jens Förster, a high-profile social psychologist, has agreed to retract multiple papers following an institutional investigation — but has also fought to keep some papers intact. Recently, one publisher agreed with his appeal, and announced it would not retract two of his papers, despite the recommendation of his former employer.

Last month, the American Psychological Association (APA) announced it would not retract two papers co-authored by Förster, which the University of Amsterdam had recommended for retraction in May, 2015. The APA had followed the university’s advice last year and retracted two other papers, which Förster had agreed to as part of a settlement with the German Society for Psychology (DGPs). But after multiple appeals by Förster and his co-authors, the publisher has decided to retain the papers as part of the scientific record.

Many voices contributed to the discussion about these two papers — in November, 2016, the University of Amsterdam announced it was rejecting the appeal by another co-author on both papers, Nira Liberman, based at Tel Aviv University in Israel. The following month, Tel Aviv University announced that it believed the articles should not be retracted, based on its own internal review.

The APA reviewed the various recommendations, according to last month’s announcement:

Continue reading Publisher won’t retract two papers, despite university’s request